Latest approaches în the surgical treatment of cutaneous malignant melanoma;Actualitǎţi în tratamentul chirurgical al melanomului malign cutanat

Chirurgia (Romania)

Volumn 108, Issue 3, 2011, Pages 301-308

  Sandru, A ^a   Bordea, C I ^a   Voinea, S C ^a   Gherghe, M ^b   Albert, P ^b   Condrea, I ^c   Blidaru, A ^a  

^a Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti   (Romania)

^b Institutul Oncologic   (Romania)

^c Spitalul Clinic de Urgen   (Romania)

Author keywords

Malignant melanoma; Sentinel lymph node biopsy; Surgical treatment

Indexed keywords

CANCER STAGING; HUMAN; LYMPHADENECTOMY; MELANOMA; METHODOLOGY; PATHOLOGY; PATIENT SELECTION; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR; TREATMENT OUTCOME;

HUMANS; LYMPH NODE EXCISION; MELANOMA; NEOPLASM STAGING; PATIENT SELECTION; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84874062876     PISSN: 12219118     EISSN: 1842368X     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Schwartz A. Robert - Skin Cancer Recognition and Management - second edition.
2. Urist M, Soong S. Melanoma and Cutaneous Malignancies in Sabiston Textbook of Surgery, 18th edition.
3. DeVita, Hellman and Rosenberg's - Cancer Principles and Practice of Oncology 8th edition.
4. Patel M, Williford P, Shumack S. Basal Cell Carcinoma in Managing Skin Cancer: Springer; 2010.
5. Stockfleth E. Squamous Cell Carcinoma In Situ. In: Managing Skin Cancer 2010.
6. Osterlind A. Epidemiology on malignant melanoma in Europe. Acta Oncol. 1992;31(8):903-8.
7. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150(2):179-85.
8. Jennings L, Murphy GM. Predicting outcome in melanoma: where are we now? Br J Dermatol. 2009;161(3):496-503. Epub 2009 Jun. 4.
9. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH et al. Revised U. K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol. 2010;163(2):238-56. Epub 2010 Jul. 1.
10. Lens MB, Nathan P, Bataille V. Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials. Arch Surg. 2007;142(9):885-91.
11. Eedy D. J. Surgical treatment of melanoma. Br J Dermatol. 2003;149(1):2-12.
12. Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AM. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009;20 Suppl 6: vi22-9.
13. Holmström H. Surgical management of primary melanoma. Semin Surg Oncol. 1992;8(6):366-9.
14. Bong JL, Herd RM, Hunter JA. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol. 2002;46(5):690-4.
15. Swanson NA, Lee KK, Gorman A, Lee HN. Biopsy techniques. Diagnosis of melanoma. Dermatol Clin. 2002;20(4):677-80.
16. Lees VC, Briggs JC. Effect of initial biopsy procedure on prognosis in Stage 1 invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg. 1991;78(9):1108-10.
17. Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009; (4): CD004835.
18. Algazi A P, Soon CW, Daud AI. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res. 2010;2:197-211.
19. Ackerman AB. A centimeter here, a centimeter there. J Am Acad Dermatol. 1996;35(2 Pt 1):279-80.
20. Comment on J Am Acad Dermatol. 1995;33(3):532-4.
21. Martin HM, Birkin AJ, Theaker JM. Malignant melanoma re-excision specimens-how many blocks? Histopathology. 1998;32(4):362-7.
22. Kirkham N. What is there to find în malignant melanoma reexcision specimens? Histopathology. 1998;32(6):566-7.
23. Comment on Histopathology. 1998;32(4):362-7.
24. Histopathology. 1998;32(4):379-80.
25. Morton DL, Thompson J F, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355(13):1307-17.
26. Erratum in N Engl J Med. 2006;355(18):1944.
27. Essner R. Sentinel lymph node biopsy and melanoma biology. Clin Cancer Res. 2006;12(7 Pt 2):2320s-2325s.
28. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg. 1992;127(4):392-9.
29. Essner R, Bostick PJ, Glass EC, Foshag LJ, Haigh PI, Wang HJ, et al. Standardized probe-directed sentinel node dissection in melanoma. Surgery. 2000;127(1):26-31.
30. Morton DL, Cochran AJ, Thompson J F, Elashoff R, Essner R, Glass EC, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302-11; discussion 311-3.
31. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22(13):2671-80.
32. Scoggins CR, Chagpar AB, Martin RC, McMasters KM. Should sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers? Nat Clin Pract Oncol. 2005;2(9):448-55.
33. Jakub J W, Pendas S, Reintgen DS. Current status of sentinel lymph node mapping and biopsy: facts and controversies. Oncologist. 2003;8(1):59-68.
34. Ranieri JM, Wagner JD, Wenck S, Johnson CS, Coleman JJ 3rd. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13(7):927-32. Epub 2006 May 22.
35. Puleo CA, Messina JL, Riker AI, Glass L F, Nelson C, Cruse C W, Johnson TM et al. Sentinel Node Biopsy for Thin Melanomas: Which Patients Should Be Considered? Cancer Control. 2005;12(4):230-5
36. Kalady M F, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003;238(4):528-35; discussion 535-7.
37. Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol. 2003;10(5):558-61.
38. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, et al. Indications for lymphatic mapping and sentinel lymphadenectomy în patients with thin melanoma. (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004;11(10):900-6. Epub 2004 Sep. 20.
39. Kesmodel SB, Karakousis GC, Botbyl JD, Canter RJ, Lewis RT, Wahl PM, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12(6):449-58. Epub 2005 Apr. 19.
40. Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003;21(7):1326-31.
41. Agnese DM, Abdessalam SF, Burak WE Jr, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery. 2003;134(4):542-7; discussion 547-8.
42. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009;7(3):308-17.
43. Mariani G, Gipponi M, Moresco L, Villa G, Bartolomei M, Mazzarol G, et al. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med. 2002;43(6):811-27.
44. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg. 2002;89(10):1223-7.
45. Warycha MA, Zakrzewski J, Ni Q, Shapiro RL, Berman RS, Pavlick AC, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (
46. Gershenwald JE, Mansfield P F, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000;7(2):160-5.
47. Scolyer RA, Murali R, Satzger I, Thompson J F. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol. 2008;17(3):165-74. Epub 2008 Jul. 18.
48. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse C W, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer. 2000;89(2):236-41.
49. Gershenwald JE, Colome MI, Lee JE, Mansfield P F, Tseng C, Lee JJ, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16(6):2253-60.
50. Koopal SA, Tiebosch AT, Albertus Piers D, Plukker J T, Schraffordt Koops H, Hoekstra HJ. Frozen section analysis of sentinel lymph nodes in melanoma patients. Cancer. 2000;89(8):1720-5.
51. Phan GQ, Messina JL, Sondak VK, Zager JS. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control. 2009;16(3):234-9.
52. Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, Flotte TJ, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg. 1999;134(4):381-7.
53. Essner R, Conforti A, Kelley MC, Wanek L, Stern S, Glass E, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol. 1999;6(5):442-9.
54. Thomas JM. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol. 2008;5(1):18-23.
55. Reintgen D, Cruse C W, Wells K, Berman C, Fenske N, Glass F, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220(6):759-67.
56. Gannon CJ, Rousseau DL Jr, Ross MI, Johnson MM, Lee JE, Mansfield P F, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006;107(11):2647-52.
57. Davids V, Kidson SH, Hanekom GS. Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node. Melanoma Res. 2003;13(3):313-24.
58. Scolyer RA, Murali R, McCarthy SW, Thompson JF. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol. 2008;25(2):100-11.
59. www.cancer.gov
60. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am. 2003;83(1):109-56.
61. Mariani G, Erba P, Manca G, Villa G, Gipponi M, Boni G, et al. Radioguided sentinel lymph node biopsy in patients with malignant cutaneous melanoma: the nuclear medicine contribution. J Surg Oncol. 2004;85(3):141-51.
62. Blaheta HJ, Schittek B, Breuninger H, Garbe C. Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma. Recent Results Cancer Res. 2001;158:137-46.
63. Bilimoria KY, Balch CM, Bentrem DJ, Talamonti MS, Ko CY, Lange JR, et al. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15(6):1566-76. Epub 2008 Apr. 15.
64. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass L F, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA. 1998;280(16):1410-5.
65. Denninghoff VC, Falco J, Kahn AG, Trouchot V, Curutchet H P, Elsner B. Sentinel node in melanoma patients: triple negativity with routine techniques and PCR as positive prognostic factor for survival. Mod Pathol. 2008;21(4):438-44. Epub 2008 Jan 25.
66. Overett TK, Shiu MH. Surgical treatment of distant metastatic melanoma. Indications and results. Cancer. 1985;56(5):1222-30.
67. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: melanoma. v. 2.2007. Available at: http://www.nccn.org/. 2010
68. Sabel MS, Griffith K, Sondak VK, Lowe L, Schwartz JL, Cimmino VM, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201(1):37-47.
69. Scheri R P, Essner R, Turner RR, Ye X, Morton DL. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol. 2007;14(10):2861-6. Epub 2007 Jul. 18.
70. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22(18):3677-84.
71. Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol. 2006;24(27):4464-71.
72. van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol. 2006;17(10):1578-85. Epub 2006 Sep. 12.
73. van Akkooi AC, de Wilt JH, Verhoef C, Eggermont AM. Cutaneous melanoma and sentinel lymph node biopsy. Ann Surg Oncol. 2008;15(6):1808-9; author reply 1810-1. Epub 2008 Feb. 2.
74. Comment on Ann Surg Oncol. 2007;14(12):3566-74.
75. Gershenwald JE, Andtbacka RH, Prieto VG, Johnson MM, Diwan AH, Lee JE, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008;26(26):4296-303. Epub 2008 Jul. 7.
76. McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008;15(3):239-47.
77. Blidaru A. Melanomul Malign Ed Univ Carol Davila 2003.
78. Patchell RA, Tibbs PA, Walsh J W, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500.
79. Miller JD. Surgical excision for single cerebral metastasis? Lancet. 1993;341(8860):1566.
80. Sondak V, Liu P, Warneke J et al. Surgical resection for stage IV melanoma: a Southwest Oncology Group Trial (S9430). J Clin Oncol 2006;24(Suppl.):8019.
81. Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89(9):1983-91.
82. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139(9):961-6; discussion 966-7.
83. Hieken TJ. The Role of Sentinel Node Biopsy in Skin Cancer http://emedicine.medscape.com/article/1126050-overview
84. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, et al. Malignant Melanoma în the 21st Century, Part 2: Staging, Prognosis, and Treatment. Mayo Clin Proc. 2007;82(4):490-513.